Dr. Yong Yue joined Laekna Therapeutics in 2018 as Chief Medical Officer. He spends most of his time working at Laekna’s US office in New Jersey, and frequently travels between Shanghai and New Jersey. He is responsible for the medical strategy and clinical development plan to move forward the company’s clinical development pipeline cross the US and China.

Dr. Yue has over 20 years of experience leading Medical Affairs in global pharmaceutical companies in the US, as well as clinical development in oncology in China and the US. Before joining Laekna, Dr. Yue served as Global Clinical Leader at Janssen Pharmaceuticals under Johnson & Johnson, leading the global clinical team to oversee clinical programs and supporting NDA submissions. He had abundant experience working with the FDA and EMA. Previously, he worked with GSK and Sanofi, leading global multi-center clinical studies in oncology, analgesics and neuroscience, with some drug candidates approved.

Prior to joining the pharmaceutical industry, Dr. Yue was a surgical oncologist with more than 10 years of clinical experience. He was a licensed physician in both China and the US. He was Attending Physician with Department of Surgical Oncology at Tianjin Medical University General Hospital, and a Clinic Fellow with Department of Surgical Oncology at University Hospital of Geneva. He was also a Resident and Fellow at Surgical Oncology of Brigham and Women’s Hospital of Harvard University Medical School.

Yong Yue obtained his MD under an 8-year medical education system from Tianjin Medical University (Medicine) and Bachelor of Science from Nankai University (Pre-Medicine). In 1994, he obtained the PhD of Medical Science from University of Geneva Medical School, a global top 25 medical school, under the federal scholarship. In 1998-1999, he was a postdoctoral research fellow at Lab for Cancer Research, College of Pharmacy, Rutgers University in the US.